<DOC>
	<DOCNO>NCT02703623</DOCNO>
	<brief_summary>The goal clinical research study find combination apalutamide ( also know ARN-509 JNJ-5602192 ) , abiraterone acetate , prednisone give either ipilimumab cabazitaxel plus carboplatin control metastatic CRPC . The safety effectiveness drug combination effect immune system also study .</brief_summary>
	<brief_title>A Dynamic Allocation Modular Sequential Trial Approved Promising Therapies Men With Metastatic Castrate Resistant Prostate Cancer ( DynaMO )</brief_title>
	<detailed_description>Study Groups : If find eligible take part study , assign Group 1 receive apalutamide , abiraterone , prednisone . After 8 week receive treatment Group 1 , blood ( 4 teaspoon ) draw biomarker testing . The result biomarker test determine whether continue study Group 2 Group 3 . If find eligible Group 2 , randomly assign ( flip coin ) 1 2 study group . This do one know one study group well , , bad group . You equal chance ( 50/50 ) assign either group : - If assign Group 2A , continue receive apalutamide , abiraterone , prednisone alone . - If assign Group 2B , receive apalutamide , abiraterone , prednisone , ipilimumab . If find eligible Group 3 , receive apalutamide , abiraterone , prednisone , plus cabazitaxel carboplatin . Study Drug Administration : Each study cycle 21 day . - You take 4 tablet abiraterone acetate 4 tablet apalutamide mouth every day study . The tablet take time every day . You take drug throughout entire study . - You eat drink anything except water 2 hour dose 1 hour dose . - You also take 1 tablet prednisone mouth 2 time every day study . Prednisone take food . The study drug bottle also include small packet ( call desiccant ) place bottle protect study drug . Do eat remove desiccant . You store study drug study bottle place pill separate container , pill container . If assign Group 2B , also receive ipilimumab vein 90 minute Day 1 Cycles 4 , 5 , 6 , 7 . If assign Group 3 , receive cabazitaxel carboplatin vein Day 1 Cycles 4 , 5 , 6 , 7 . You receive cabazitaxel vein 60 minute receive carboplatin , also vein , 60 minute . Study Visits : On Day 1 Cycles 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , every 2 cycle one year , every 4 cycle : - You physical exam . - Blood ( 3 teaspoon ) draw routine test , test liver function , measure PSA level . Every 2 week first 9 week ( Cycles 1-3 ) every week Cycles 4-7 , blood ( 3-4 teaspoon ) draw routine test check thyroid ( Cycle 1 ) . At Week 3 Cycle 3 : - You physical exam . - Blood ( 3 teaspoon ) draw routine test , test liver function , measure PSA level . - You bone scan either CT scan MRI abdomen pelvis . If doctor think need , also chest CT scan . - Blood ( 3 teaspoon ) urine collect biomarker test . - A bone marrow biopsy aspiration collect biomarker testing . If Group 2B , Day 1 Cycles 4 , 5 , 6 , 7 8 , blood ( 1 teaspoon ) drawn test thyroid adrenal function . If Group 2A , Day 1 Cycle 8 : - Blood ( 3 teaspoon ) draw biomarker testing . - A bone marrow biopsy aspiration collect biomarker testing . If Group 2B , 3 week last dose ipilimumab : - Blood ( 3 teaspoon ) draw biomarker test - A bone marrow biopsy aspiration collect biomarker testing . If Group 3 , 3 week last dose cabazitaxel carboplatin : - Blood ( 3 teaspoon ) draw biomarker testing . - A bone marrow biopsy aspiration collect biomarker testing . If Group 2A 2B , Weeks 21 , 33 , 45 , every 16 week : - You bone scan , either CT scan MRI abdomen pelvis . If doctor think need , also chest CT scan . - Blood ( 3 teaspoon ) urine collect biomarker test . If Group 3 , Weeks 15 , 21 , 33 , 45 , 57 , every 16 week : - You bone scan , either CT scan MRI abdomen pelvis . If doctor think need , also chest CT scan . - Blood ( 3 teaspoon ) urine collect biomarker test . If study doctor think need , may additional bone scan CT scan MRIs abdomen , pelvis , chest check status disease . Length Treatment : You may continue take study drug long doctor think best interest . You may longer able take study drug disease get bad , intolerable side effect occur , unable follow study direction . If study drug become commercially available study , may begin receive study . It also possible continue receive study drug part extension study , government-sponsored private health program . It also possible and/or insurance provider pay drug become commercially available doctor wish continue . The study doctor tell thing happen . End-of-Treatment Visit : About 14 day last dose study drug , return clinic end-of-treatment visit . At visit : - You physical exam . - Blood ( 4 teaspoon ) urine collect routine biomarker test . This blood also use check liver function , PSA testosterone level . - You bone scan MRI CT scan check status disease . - A bone marrow biopsy aspiration collect biomarker testing . About 30 day last dose study drug , ask . If return clinic , one study staff member call check . This call last 5-10 minute . Long-Term Follow-Up : A member study staff check ask every 6 month last dose study drug . This could either phone call review medical and/or record . If contact phone , call last minute . This investigational study . Apalutamide FDA approve commercially available . It currently use research purpose . Prednisone FDA-approved commercially available corticosteroid . Ipilimumab FDA approve treat metastatic melanoma . Abiraterone acetate , cabazitaxel carboplatin FDA-approved commercially available treatment metastatic CRPC . It consider investigational give combination drug treatment metastatic CRPC . The study doctor explain study drug design work . Up 265 participant enrol multicenter study . Up 265 take part MD Anderson .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Willing able provide write informed consent . 2 . Male age 18 year . 3 . Histologically cytologically confirm adenocarcinoma prostate . 4 . Presence metastatic disease document image study ( bone scan , CT and/or MRI scan ) . 5 . Patients must document evidence progressive disease define follow : ) PSA progression : minimum 2 rise value ( 3 measurement ) obtain minimum 7 day apart last result least &gt; /= 1.0 ng/mL ; b ) New increase nonbone disease ( RECIST 1.1 criterion ) ; c ) Positive bone scan 2 new lesion ( PCWG3 ) . 6 . Surgically ongoing medically castrate , baseline testosterone level &lt; /= 50 ng/dL ( &lt; /= 2.0 nM ) . 7 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status &lt; /= 2 . 8 . Hemoglobin &gt; /= 9.0 g/dL independent transfusion growth factor within 3 month prior enrollment . 9 . Platelet count &gt; /= 100,000/uL independent transfusion growth factor within 3 month prior enrollment . 10 . Serum albumin &gt; /= 3.0g/dL . 11 . Medications know low seizure threshold must discontinue substitute least 4 week prior study entry . 12 . Absolute neutrophil count ( ANC ) &gt; /= 1,500/mm3 . 13 . Calculated creatinine clearance ( CockcroftGault Equation ) &gt; /= 40 mL/min . 14 . Serum potassium &gt; /= Institutional Lower Limit Normal ( ILLN ) . 15 . Serum magnesium &gt; /= ILLN . 16 . Serum bilirubin &lt; 1.5 x Institutional Upper Limit Normal ( IULN ) ( except patient know Gilbert 's disease ) . 17 . Serum AST ALT &lt; 2.5 x IULN patient without liver metastasis . For patient liver metastasis AST ALT &lt; 5 x IULN allow . 18 . Able swallow study drug whole tablet/capsule . 19 . Male subject female partner childbearing potential pregnant must agree use two acceptable method contraception donate sperm time Screening 3 month last dose study treatment . 20 . Patients must agree tissue collection correlative study ( include participation PA130291 PA130247 MD Anderson participant ) specify timepoints . 1 . Any prior treatment : Ipilimumab 2 . Treatment within 28 day Cycle1 Day1 : Any systemic therapy prostate cancer ( exception LHRH agonists LHRH antagonists testosterone suppression , bisphosphonates RANKligand inhibitor bone metastasis allow ) . Any investigational product Any medication list Appendix H. 3 . Treatment within 12 month Cycle 1 Day 1 Cyp17lyase inhibitor , 2nd generation AR antagonist ( e.g . enzalutamide ) , cabazitaxel carboplatin . 4 . Patients treat Cyp17lyase inhibitor , 2nd generation AR antagonist ( e.g . enzalutamide ) , cabazitaxel carboplatin whose disease progress treatment within 3 month discontinuation . Patients receive treatment 12 month study entry whose disease progress treatment within 3 month discontinuation allow study . 5 . Patients whose disease refractory ( defined evidence disease progression drug within 3 month discontinuation ) 2 line chemotherapy . Any number chemotherapy patient 's disease refractory allow , long time treatment exceed 6 month ( count day 1 cycle 1 day 1 last cycle treatment ) . 6 . Flutamide ( Eulexin ) treatment within 4 week Cycle 1 , Day 1 Bicalutamide ( Casodex ) nilutamide ( Nilandron ) within 6 week Cycle 1 Day 1 ( Exceptions : progression document prior time interval , patient deem treat physician highly unlikely respond AR inhibitor withdrawal ( e.g . PSA decline &gt; /= 3 month response AR inhibitor give second line later intervention , patient symptom attribute disease progression ) 3 day washout prior Cycle 1 , Day 1 require . 7 . Radiation therapy treatment primary tumor within 6 week Cycle 1 , Day 1 . Patients receive palliative radiation single site recover eligible . 8 . Any chronic medical condition require high dose corticosteroid 10mg prednisone/prednisolone daily . Use inhale , intranasal , intraarticular topical steroid acceptable , short course ( i.e . &lt; /= 1 day ) corticosteroid prevent reaction IV contrast use CT scan . 9 . Active infection ( require oral IV antibiotic antiviral therapy ) medical condition would make prednisone/prednisolone ( corticosteroid ) use contraindicate . Known history test positive human immunodeficiency virus ( HIV ) know acquired immunodeficiency syndrome ( AIDS ) . 10 . A malignancy [ one treat study ] require radiotherapy systemic treatment within past 5 year , &gt; /= 30 % probability recurrence within 24 month ( except nonmelanoma skin cancer Ta urothelial carcinoma ) . 11 . Uncontrolled hypertension ( systolic BP &gt; /= 140 mmHg diastolic BP &gt; /= 90 mmHg ) . Patients history hypertension allow provide blood pressure control antihypertensive treatment . 12 . Prolonged QTc interval preentry electrocardiogram ( &gt; /= 450 msec ) . 13 . Known active symptomatic viral hepatitis chronic liver disease . 14 . Clinically significant heart disease evidence myocardial infarction , arterial thrombotic event past 6 month , severe unstable angina , history clinically significant ventricular arrhythmia ( ventricular tachycardia , ventricular fibrillation , Torsade de pointes ) , New York Heart Association ( NYHA ) Class IIIIV heart disease cardiac ejection fraction measurement &lt; 40 % baseline . 15 . Autoimmune disease : Patients history inflammatory bowel disease ( include Crohn 's disease ulcerative colitis ) autoimmune disorder rheumatoid arthritis , autoimmune thyroiditis , autoimmune hepatitis , systemic progressive sclerosis [ scleroderma variant ] , Systemic Lupus Erythematosus , autoimmune vasculitis [ e.g. , Wegener 's Granulomatosis ] autoimmune neuropathy ( GuillainBarre syndrome ) exclude study . Vitiligo adequately control endocrine deficiency hypothyroidism exclusionary . 16 . Patients history illness put current risk bowel perforation acute diverticulitis , intraabdominal abscess , GI obstruction abdominal carcinomatosis 17 . History seizure know condition may predispose seizure ( include limit prior stroke , loss consciousness within 1 year prior randomization , brain arteriovenous malformation ; intracranial mass schwannomas meningiomas cause edema mass effect ) . 18 . Gastrointestinal disorder affect absorption . 19 . Any underlying medical psychiatric condition , opinion Investigator , make administration study drug hazardous obscure interpretation adverse event . 20 . Untreated symptomatic spinal cord compression . 21 . Prisoners subject involuntarily incarcerate . 22 . Subjects compulsorily detain treatment either psychiatric physical ( eg , infectious disease ) illness .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Prostate cancer</keyword>
	<keyword>Metastatic castration-resistant prostate cancer bone</keyword>
	<keyword>mCRPC</keyword>
	<keyword>Adenocarcinoma prostate</keyword>
	<keyword>Biomarkers</keyword>
	<keyword>Abiraterone Acetate</keyword>
	<keyword>Zytiga</keyword>
	<keyword>Prednisone</keyword>
	<keyword>ARN509</keyword>
	<keyword>Ipilimumab</keyword>
	<keyword>Yervoy</keyword>
	<keyword>BMS-734016</keyword>
	<keyword>MDX010</keyword>
	<keyword>Cabazitaxel</keyword>
	<keyword>Jevtana</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>Paraplatin</keyword>
</DOC>